EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSBTAG00000013498
Gene Symbol: HTR2A
8 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSBTAG00000039772
Gene Symbol: HTR2B
8 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSBTAG00000054073
Gene Symbol: HTR2C
3 Cross references
239 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSBTAG00000010791
Gene Symbol: HTR3A
3 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSBTAG00000031330
Gene Symbol: HTR3B
3 Enzyme and pathways 5 Cross references
187 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSBTAG00000010837
Gene Symbol: HTR4
8 Enzyme and pathways 5 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSBTAG00000002891
Gene Symbol: HTR5A
8 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSBTAG00000008783
Gene Symbol: HTR7
10 Enzyme and pathways 5 Cross references
233 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSBTAG00000047136
Gene Symbol: LOC101902490
15 Enzyme and pathways 4 Cross references
180 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBTAG00000005039
Gene Symbol: ARAF
7 Enzyme and pathways 5 Cross references
204 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSBTAG00000017976
Gene Symbol: ABL1
32 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSBTAG00000001141
Gene Symbol: ADAM17
5 Enzyme and pathways 5 Cross references
296 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).